Key Insights

Highlights

Success Rate

86% trial completion

Published Results

28 trials with published results (31%)

Research Maturity

51 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

9.0%

8 terminated out of 89 trials

Success Rate

86.4%

-0.1% vs benchmark

Late-Stage Pipeline

8%

7 trials in Phase 3/4

Results Transparency

55%

28 of 51 completed with results

Key Signals

28 with results86% success

Data Visualizations

Phase Distribution

79Total
Not Applicable (12)
Early P 1 (1)
P 1 (23)
P 2 (36)
P 3 (3)
P 4 (4)

Trial Status

Completed51
Unknown9
Active Not Recruiting8
Terminated8
Recruiting6
Not Yet Recruiting3

Trial Success Rate

86.4%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (89)

Showing 20 of 20 trials
NCT06309992Phase 3Completed

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

NCT07553663Phase 1Not Yet RecruitingPrimary

Evaluating the Pharmacokinetics and Safety of Miricorilant

NCT06108219Phase 2Active Not RecruitingPrimary

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

NCT05384652Active Not Recruiting

Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment

NCT04104321Phase 3SuspendedPrimary

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

NCT06947304Phase 1RecruitingPrimary

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

NCT06168383Phase 2CompletedPrimary

To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .

NCT06843148Not ApplicableRecruiting

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

NCT05989711Phase 2CompletedPrimary

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT00666016Phase 2CompletedPrimary

Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT06724913Not ApplicableActive Not RecruitingPrimary

Efficacy and Tolerability of a Specialized Food Products for Dietary Therapeutic and Preventive Nutrition Based on Ice Cream (Ice Cream With Brazzein, Maltitol and Oligofructose; Ice Cream With Brazzein, Erythritol, Maltitol and Inulin) Compared to Standard (Sundae) Ice Cream

NCT02754037Active Not Recruiting

Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study

NCT04820036Not ApplicableActive Not RecruitingPrimary

A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)

NCT02612662Phase 1CompletedPrimary

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

NCT04880031Phase 2CompletedPrimary

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

NCT04004325Phase 1TerminatedPrimary

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

NCT05842512Phase 2RecruitingPrimary

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

NCT07180745Phase 4Not Yet Recruiting

Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

NCT07133854Not ApplicableNot Yet Recruiting

How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver

NCT06024408Phase 1Completed

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

Scroll to load more

Research Network

Activity Timeline